Department of Respiratory Medicine, Shanghai Pulmonary Hospital, Tongji University School of Medicine, 200433, Shanghai, China.
Respir Res. 2013 Feb 11;14(1):18. doi: 10.1186/1465-9921-14-18.
The diagnosis of sarcoidosis is still a significant challenge in China because of the need to exclude other diseases including granulomatous infections and malignancies that may be clinically and radiographically similar. The specific aim of the study is to search for serum protein biomarkers of sarcoidosis and to validate their clinical usefulness in differential diagnosis.
Serum samples were collected from patients with sarcoidosis (n = 37), and compared to those from patients with tuberculosis (n = 20), other pulmonary diseases (n = 20), and healthy volunteers (n = 20) for determination of sarcoidosis-specific or -associated protein expression profiles. The first part of this study focused on proteomic analysis of serum from patients with sarcoidosis to identify a pattern of peptides capable of differentiating the studied populations using the ClinProt profiling technology based on mass spectrometry. Enzyme Linked Immunosorbent Assay (ELISA) was then used to verify corresponding elevation of the serum protein concentration of the potential biomarkers in the same patients sets. Receiver operating characteristic curve (ROC) analyses was performed to determine the optimal cutoff value for diagnosis. Immunohistochemistry was carried out to further confirm the protein expression patterns of the biomarkers in lung tissue.
An unique protein peak of M/Z 3,210 Daltons (Da) was found to be differentially expressed between the sarcoidosis and control groups and was identified as the N-terminal peptide of 29 amino acids (94-122) of serum amyloid A (SAA). ELISA confirmed that the serum SAA level was significantly higher in the sarcoidosis group than that of the other 3 control groups (p < 0.05). The cutoff for serum SAA concentration determined by ROC analysis was 101.98 ng/ml, with the sensitivity and specificity of 96.3% and 52.5%, respectively. Immunohistochemical staining showed that the SAA depositions in lung tissue of the sarcoidosis patients were also significantly more intense than in non-sarcoid lung tissue (p < 0.05).
This is the first study to investigate serum protein markers in Chinese subjects with sarcoidosis. This study shows that the serum SAA expression profiles were different between the sarcoidosis and non-sarcoidosis groups. SAA may be a potential serum biomarker for ruling-out the diagnosis of sarcoidosis in Chinese subjects.
在中国,由于需要排除可能在临床上和影像学上相似的肉芽肿性感染和恶性肿瘤等其他疾病,结节病的诊断仍然是一个重大挑战。本研究的具体目的是寻找结节病的血清蛋白标志物,并验证其在鉴别诊断中的临床应用价值。
收集结节病患者(n=37)、肺结核患者(n=20)、其他肺部疾病患者(n=20)和健康志愿者(n=20)的血清样本,以确定结节病特异性或相关性蛋白表达谱。本研究的第一部分侧重于使用基于质谱的 ClinProt 分析技术分析结节病患者血清的蛋白质组学,以鉴定一种能够区分研究人群的肽模式。然后使用酶联免疫吸附测定(ELISA)验证同一患者组中潜在生物标志物的血清蛋白浓度相应升高。进行受试者工作特征曲线(ROC)分析以确定用于诊断的最佳截断值。进行免疫组织化学以进一步确认生物标志物在肺组织中的蛋白表达模式。
发现 M/Z 3210 道尔顿(Da)的独特蛋白峰在结节病组和对照组之间存在差异表达,被鉴定为血清淀粉样蛋白 A(SAA)的 29 个氨基酸(94-122)的 N 端肽。ELISA 证实,结节病组患者血清 SAA 水平明显高于其他 3 组对照组(p<0.05)。ROC 分析确定的血清 SAA 浓度截断值为 101.98ng/ml,灵敏度和特异性分别为 96.3%和 52.5%。免疫组织化学染色显示,结节病患者肺组织中的 SAA 沉积也明显强于非结节病肺组织(p<0.05)。
这是第一项研究中国结节病患者血清蛋白标志物的研究。本研究表明,结节病组和非结节病组的血清 SAA 表达谱不同。SAA 可能是排除中国人群结节病诊断的潜在血清标志物。